Close Menu

NEW YORK – BioSpyder Technologies on Wednesday filed a civil action in  US District Court for the Northern District of California seeking a declaratory judgement that the firm's TempO-Seq gene expression profiling assay does not infringe a patent held by HTG Molecular Diagnostics.

BioSpyder's actions relates to US Patent No. 8,741,564 held by HTG covering a quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements. 

The Carlsbad, California-startup firm said that HTG has repeatedly and baselessly asserted that BioSpyder has infringed the '564 patent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.